Ultra Nasdaq Biotechnology
ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the NASDAQ Biotechnology® Index.
Product Menu:
Index/Benchmark Summary
The NASDAQ Biotechnology Index is a modified capitalization weighted index that includes securities of The NASDAQ Stock Market listed companies that are classified as either biotechnology or pharmaceutical. The securities also meet other eligibility criteria determined by The NASDAQ OMX Group, Inc., including minimum market capitalization and liquidity requirements.
As of 3/31/12
Fundamentals
| Total Number of Companies |
Price/Earnings Ratio |
Price/Book Ratio |
Dividend Yield * (%) |
Average Index Market Capitalization |
|---|---|---|---|---|
| 117 | 81.64 | 4.72 | 0.25 | $3.37 billion |
* Derivative contracts are priced to reflect the underlying index yield and will not generate dividend income. Because ProShares invest in derivatives, they will not have dividend distributions that reflect those of their applicable indexes.
| Top 10 Index Companies ‡ | Weight |
|---|---|
| Alexion Pharmaceuticals Inc. | 7.66% |
| Amgen Inc. | 7.18% |
| Regeneron Pharmaceuticals Inc. | 6.69% |
| Celegene Corp. | 6.31% |
| Gilead Sciences Inc. | 5.45% |
| Biogen Idex Inc. | 4.92% |
| TEVA Pharmaceutical-SP ADR | 4.62% |
| Perrigo Co. | 4.01% |
| Vertex Pharmaceuticals Inc. | 3.50% |
| Mylan Inc. | 2.98% |
‡ ProShares may invest in financial instruments (including derivatives) that, in combination, should have similar daily price return characteristics to the fund's benchmark.
| Index Sector Weightings § | Weight |
|---|---|
| Biotechnology | 61.89% |
| Pharmaceuticals | 34.39% |
| Health Care-Products | 3.50% |
| Commercial Services | 0.22% |
§ Sum of weightings may not equal 100% due to rounding.